3 ms·
The upper bound isn't really relevant though, because of course any company can spend infinitely much on anything, and will if they're trying to maximize the am
by Alex3917 9y ago
The upper bound isn't really relevant though, because of course any company can spend infinitely much on anything, and will if they're trying to maximize the amount of time they can sell the drug while it's under patent. The only thing that matters is how much the least expensive drug approvals cost.
- aaavl2821 9y agoI'm probably taking you too literally but companies can't spend infinite amounts because they don't have infinite money The upper bound is actually very relevant. Those $300M studies are cardiovascular outcomes studies, which are required for many diabetes / cardiovascular drugs, and those expensive studies have basically stifled innovation in those areas because the cost of developing those drugs is too high compared to the expected profits Not sure I understand the statement that the only thing that matters is how much the least expensive drug approvals cost?